Read by QxMD icon Read

Neoadjuvant chemotherapy

Jean-Marc Classe, Cecile Loaec, P Gimbergues, S Alran, C Tunon de Lara, P F Dupre, Roman Rouzier, C Faure, N Paillocher, M P Chauvet, G Houvenaeghel, M Gutowski, P De Blay, J L Verhaeghe, E Barranger, C Lefebvre, C Ngo, G Ferron, C Palpacuer, L Campion
PURPOSE: GANEA2 study was designed to assess accuracy and safety of sentinel lymph node (SLN) after neo-adjuvant chemotherapy (NAC) in breast cancer patients. METHODS: Early breast cancer patients treated with NAC were included. Before NAC, patients with cytologically proven node involvement were allocated into the pN1 group, other patient were allocated into the cN0 group. After NAC, pN1 group patients underwent SLN and axillary lymph node dissection (ALND); cN0 group patients underwent SLN and ALND only in case of mapping failure or SLN involvement...
October 20, 2018: Breast Cancer Research and Treatment
Anna M Mazor, Alina M Mateo, Lyudmila Demora, Elin R Sigurdson, Elizabeth Handorf, John M Daly, Allison A Aggon, Penny R Anderson, Stephanie E Weiss, Richard J Bleicher
PURPOSE: Breast conservation therapy (BCT) is standard for T1-T2 tumors, but early trials excluded breast cancers > 5 cm. This study was performed to assess patterns and outcomes of BCT for T3 tumors. METHODS: We reviewed the National Cancer Database (NCDB) for noninflammatory breast cancers > 5 cm, between 2004 and 2011 who underwent BCT or mastectomy (Mtx) with nodal evaluation. Patients with skin or chest wall involvement were excluded. Patients having clinical T3 tumors were analyzed to determine outcomes based upon presentation, with those having pathologic T3 tumors, subsequently assessed, irrespective of presentation...
October 20, 2018: Breast Cancer Research and Treatment
Yu Han, Wei Guo, Tingting Ren, Yi Huang, Shidong Wang, Kuisheng Liu, Bingxin Zheng, Kang Yang, Hongliang Zhang, Xin Liang
Osteosarcoma (OS) is a common, malignant musculoskeletal tumor in young people. Neoadjuvant chemotherapy has improved the survival of osteosarcoma patients but with limited benefit due to metastasis. Tumor-associated macrophages (TAMs) are involved in various mechanisms of tumor biology, which include oncogenesis, drug resistance, and tumor immune escape, as well as tumor metastasis. In this study, we proved that TAMs possess the ability to promote OS cell migration and invasion by upregulating COX-2, MMP9, and phosphorylated STAT3 and to induce the epithelial-mesenchymal transition (EMT)...
October 18, 2018: Cancer Letters
Soshi Kusunoki, Yasuhisa Terao, Takashi Hirayama, Kazunari Fujino, Takafumi Ujihira, Tsuyoshi Ota, Satoru Takeda
OBJECTIVE: The aim of this study was to evaluate the outcomes of neoadjuvant chemotherapy (NAC) with bevacizumab (Bev) at our institute. MATERIALS AND METHODS: Eleven patients with stage IIIC or IV peritoneal/ovarian cancer who underwent interval debulking surgery (IDS) after NAC with Bev between December 2014 and December 2016 were enrolled retrospectively (TCB group). As a control group, we enrolled 13 patients evaluated between December 2012 and December 2014 who underwent IDS and received NAC without Bev (TC group)...
October 2018: Taiwanese Journal of Obstetrics & Gynecology
Peng-Hui Wang
No abstract text is available yet for this article.
October 2018: Taiwanese Journal of Obstetrics & Gynecology
Oliver Strobel, John Neoptolemos, Dirk Jäger, Markus W Büchler
Pancreatic cancer is likely to become the second most frequent cause of cancer-associated mortality within the next decade. Surgical resection with adjuvant systemic chemotherapy currently provides the only chance of long-term survival. However, only 10-20% of patients with pancreatic cancer are diagnosed with localized, surgically resectable disease. The majority of patients present with metastatic disease and are not candidates for surgery, while surgery remains underused even in those with resectable disease owing to historical concerns regarding safety and efficacy...
October 19, 2018: Nature Reviews. Clinical Oncology
Georgios Klironomos, Lior Gonen, Karolyn Au, Eric Monteiro, Alireza Mansouri, Mazda Keki Turel, Ian Witterick, Alan Vescan, Gelareh Zadeh, Fred Gentili
During the last two decades evolution of the endoscopic endonasal approaches (EEA) has offered the option of minimally invasive techniques in the management of esthesioneuroblastomas (ENB), either as endoscope assisted cranial resection or as pure endoscopic procedures. This study presents the use of pure EEA in the management of ENB in our center, along with a literature review. We retrospectively reviewed the clinical, radiology and pathology records of patients with ENB treated during the period July 2006 to January 2016...
October 16, 2018: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
Misako Nakagawa, Mayumi Ikeuchi, Masami Morimoto, Hirokazu Takechi, Hiroaki Toba, Takahiro Yoshida, Kazumasa Okumura, Naoki Hino, Aya Nishisho, Akira Tangoku
BACKGROUND: To improve the pathological complete response (pCR) rate, we devised new neoadjuvant chemotherapy. Efficacy and safety of the oral fluoropyrimidine derivative S-1 (Taiho Pharmaceutical Co, Tokyo, Japan) combined with low-dose docetaxel (S-1+DOC) were evaluated. PATIENTS AND METHODS: Patients were treated with docetaxel (40 mg/m2 intravenously on day 1) and S-1 (40 mg/m2 orally twice per day on days 1-14) every 3 weeks for 4 cycles. In accord with the Response Evaluation Criteria In Solid Tumors version 1...
September 27, 2018: Clinical Breast Cancer
I-Sanna Gibbons-Fideler, Hiroaki Nitta, Adrian Murillo, Gary Tozbikian, Peter Banks, Anil V Parwani, Zaibo Li
Objectives: Either immunohistochemistry (IHC) or in situ hybridization (ISH) can be used to determine human epidermal growth factor receptor 2 (HER2) status. Breast cancers (BCs) with HER2 IHC-negative (IHC-) and ISH-amplified (ISH+) results have been rarely reported but not well studied. We investigated the frequency of HER2 IHC-/ISH+ BCs and their response to anti-HER2 neoadjuvant chemotherapy (NAC). Methods: Seventeen BCs with HER2 IHC-/ISH+ results were identified from 1,107 consecutive invasive BCs (1...
October 18, 2018: American Journal of Clinical Pathology
S-P Zhang, X Li, H Li, X-H Sun, X-F Yan
OBJECTIVE: We examined the clinical significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on the Glutaminase 1 gene (GLS1) expression. PATIENTS AND METHODS: 278 patients admitted to Qianfoshan Hospital Affiliated to Shandong University with osteosarcoma were randomly divided into the study group and the control group. Patients in the study group had 3-4 courses of cisplatin, ifosfamide, and adriamycin (DIA) chemotherapy before surgical excision, while no chemotherapy was used in the control group before the surgery...
October 2018: European Review for Medical and Pharmacological Sciences
Jeffrey M Cochran, David R Busch, Anaïs Leproux, Zheng Zhang, Thomas D O'Sullivan, Albert E Cerussi, Philip M Carpenter, Rita S Mehta, Darren Roblyer, Wei Yang, Keith D Paulsen, Brian Pogue, Shudong Jiang, Peter A Kaufman, So Hyun Chung, Mitchell Schnall, Bradley S Snyder, Nola Hylton, Stefan A Carp, Steven J Isakoff, David Mankoff, Bruce J Tromberg, Arjun G Yodh
Ideally, neoadjuvant chemotherapy (NAC) assessment should predict pathologic complete response (pCR), a surrogate clinical endpoint for 5-year survival, as early as possible during typical 3- to 6-month breast cancer treatments. We introduce and demonstrate an approach for predicting pCR within 10 days of initiating NAC. The method uses a bedside diffuse optical spectroscopic imaging (DOSI) technology and logistic regression modeling. Tumor and normal tissue physiological properties were measured longitudinally throughout the course of NAC in 33 patients enrolled in the American College of Radiology Imaging Network multicenter breast cancer DOSI trial (ACRIN-6691)...
October 2018: Journal of Biomedical Optics
Thomas J Vogl, Ahmed I A Mekkawy, Duaa B Thabet, Mostafa El-Sharkaway, Hosam M Kamel, Moritz H Albrecht, Nagy N N Naguib, Afaf Hassan
PURPOSE: To retrospectively evaluate tumor response, local tumor control, and patient survival after the treatment of pulmonary metastases using transpulmonary chemoembolization (TPCE) in palliative and neoadjuvant intent. MATERIALS AND METHODS: One hundred forty-three patients (mean age 56.7 ± 13.4 years) underwent repetitive TPCE (mean number of sessions 5.8 ± 2.9) between June 2005 and April 2017 for the treatment of unresectable lung metastases, not responding to systemic chemotherapy...
October 18, 2018: European Radiology
Yudiana Wayan, Pratiwi Dinar Ayu, Oka A A Gde, Niryana Wayan, I Putu Eka Widyadharma
BACKGROUND: Radical cystectomy is the standard treatment for nonmetastatic bladder cancer (muscle-invasive and selective superficial bladder cancer). There are many types of urinary diversion after this procedure; the ileal conduit is the most and simplest one. AIM: To asses clinical, pathological profile, early complication, functional and oncological outcome after radical cystectomy and ileal conduit for muscle-invasive bladder cancer patients. METHOD: Between January 2013 and December 2016, there were 68 patients diagnosed with bladder cancer...
September 25, 2018: Open Access Macedonian Journal of Medical Sciences
Yong Jae Lee, Young Shin Chung, Jung-Yun Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Young Tae Kim
AIMS: We evaluated the prognostic significance of postoperative re-elevation of cancer antigen-125 (CA-125) levels in patients with ovarian cancer and preoperative normalization of CA-125 levels after neoadjuvant chemotherapy (NAC). METHODS: The data of 103 patients with preoperative CA-125 normalization after NAC at the Yonsei Cancer Hospital (2006-2017) were analyzed. We compared the clinical characteristics and survival outcomes among patients with normal postoperative CA-125 levels and those with re-elevated CA-125 levels after interval debulking surgery (IDS)...
October 11, 2018: European Journal of Surgical Oncology
S Loibl, K E Weber, K M Timms, E P Elkin, E Hahnen, P A Fasching, B Lederer, C Denkert, A Schneeweiss, S Braun, C T Salat, M Rezai, J U Blohmer, D M Zahm, C Jackisch, B Gerber, P Klare, S Kümmel, C Schem, S Paepke, R Schmutzler, K Rhiem, S Penn, J Reid, V Nekljudova, A-R Hartman, G von Minckwitz, M Untch
Background: In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Here, we present survival data and the potential prognostic and predictive role of homologous recombination deficiency (HRD). Patients and Methods: Patients were randomized to paclitaxel plus non-pegylated liposomal doxorubicin (Myocet®) (PM) or PM plus carboplatin (PMCb)...
October 18, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Christopher Kuo, Paul M Kent
Neoadjuvant chemotherapy for osteosarcoma of the jaw (OSJ) remains controversial despite being a standardized treatment in osteosarcoma of the long bones. We present a case of a 22-year-old male with OSJ and performed a retrospective systemic review of previously published literatures of OSJ. We identified 27 articles: 7% recommended neoadjuvant chemotherapy, 22% recommended adjuvant chemotherapy, 19% recommended both neoadjuvant and adjuvant chemotherapy, 33% recommended against chemotherapy and 19% stated the role of chemotherapy is unknown...
October 16, 2018: Journal of Pediatric Hematology/oncology
Yoichiro Kato, Hitoshi Zembutsu, Ryo Takata, Tomohiko Matsuura, Renpei Kato, Mitsugu Kanehira, Kazuhiro Iwasaki, Noriyuki Yamada, Toyomasa Katagiri, Tamotsu Sugai, Tomoaki Fujioka, Yusuke Nakamura, Wataru Obara
The present study established systems to predict the chemo-sensitivity of muscle invasive bladder cancer (MIBC) for neoadjuvant chemotherapy (NAC) with methotrexate, vinblastine, doxorubicin plus cisplatin (M-VAC) and carboplatin plus gemcitabine (CaG) by analyzing microarray data. The primary aim of the study was to investigate whether the clinical response would increase by combining these prediction systems. Treatment of each MIBC case was allocated into M-VAC NAC, CaG NAC, surgery, or radiation therapy groups by their prediction score (PS), which was calculated using the designed chemo-sensitivity prediction system...
November 2018: Oncology Letters
Elizabeth Hope Cain, Ashirbani Saha, Michael R Harowicz, Jeffrey R Marks, P Kelly Marcom, Maciej A Mazurowski
PURPOSE: To determine whether a multivariate machine learning-based model using computer-extracted features of pre-treatment dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict pathologic complete response (pCR) to neoadjuvant therapy (NAT) in breast cancer patients. METHODS: Institutional review board approval was obtained for this retrospective study of 288 breast cancer patients at our institution who received NAT and had a pre-treatment breast MRI...
October 16, 2018: Breast Cancer Research and Treatment
C Denkert, S Loibl, J Budczies, S Wienert, F Klauschen
BACKGROUND: Tumor-infiltrating lymphocytes (TILs) have been identified as prognostic parameter in breast cancer. OBJECTIVES: The aim of this review article is to provide an overview on the clinical and analytical validation of TILs in breast cancer. MATERIALS AND METHODS: Summary of international guidelines of the TIL working group as well as clinical and translational studies. RESULTS, CONCLUSIONS: Breast carcinomas with a high TIL level have an improved response to neoadjuvant chemotherapy...
October 16, 2018: Der Pathologe
Michael A Mitchell, Kevin Hogan, Kayvan Amjadi
A 61-year-old woman with locally advanced, high-grade urothelial cell carcinoma was treated with the anti-programmed death-ligand 1 antibody atezolizumab. She initially received neoadjuvant chemotherapy and surgery that led to clinical and radiographic remission at the time of atezolizumab initiation. Within 3 months she developed new mediastinal and hilar lymphadenopathy as well as pulmonary nodules in a pattern characteristic of pulmonary sarcoidosis. Mediastinal lymph node biopsy by endobronchial ultrasound demonstrated noncaseating granulomas without evidence of malignancy or infection...
October 2018: Immunotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"